These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 28821714)

  • 21. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT.
    Duan C; He B; Wang Y; Liu W; Bao W; Yu L; Xin J; Gui H; Lei J; Yang Z; Liu J; Tao W; Qin J; Luo J; Dong Z
    Sci Rep; 2024 Aug; 14(1):20199. PubMed ID: 39215105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
    Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage.
    Huang G; Ouyang M; Xiao K; Zhou H; Zhong Z; Long S; Li Z; Zhang Y; Li L; Xiang S; Ding X
    Life Sci; 2024 Nov; 357():123111. PubMed ID: 39369843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O
    Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M
    J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance.
    Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X
    Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
    Cai T; Liu Y; Xiao J
    Cancer Med; 2018 Apr; 7(4):1404-1415. PubMed ID: 29479863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.